2025 Q4 -tulosraportti
Vain PDF
9 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 480 | - | - | ||
| 515 | - | - | ||
| 82 | - | - | ||
| 393 | - | - | ||
| 7 050 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 min sittenYou might be right about that—such things often happen faster than people expect, especially if a buyer with strong incentives suddenly appears or if the market turns. At the same time, it's easy to overestimate the pace. Sales processes often take time due to due diligence, negotiations, and regulatory matters, even when interest is high. What makes you think it could happen sooner than anticipated? Are there concrete signals, or more of a gut feeling based on the company's development?
·23 min sitten250 MILLION SEEMS LIKE LITTLE. BUT CIRCIO DOESN'T NEED MORE. 🧬♟️ Lilly spent $9.4 billion on two deals. BMS spent $1.5 billion. AbbVie $2.1 billion. And Circio? 250 million kroner. Here's what no one is talking about: Circio is not a pharmaceutical company. They are a platform. That means Big Pharma pays for the research. Not Circio. The ongoing CNS study with one of the world's five largest pharmaceutical companies? Fully financed by them. Circio holds the key. Others foot the bill. 250 million is enough because they don't need to finance everything themselves. They license the technology, bring in non-dilutive capital from partners, and build parallel collaborations while others pay to test. It's not a weakness to be small. It's the business model. We know what we own. ♟️🧱🍷·2 min sittenYou might be right about that—such things often happen faster than people expect, especially if a buyer with strong incentives suddenly appears or if the market turns. At the same time, it's easy to overestimate the pace. Sales processes often take time due to due diligence, negotiations, and regulatory matters, even when interest is high. What makes you think it could happen sooner than anticipated? Are there concrete signals, or more of a gut feeling based on the company's development?
·31 min sittenCircio Holding ASA: Cancellation of subsequent offering Reference is made to the stock exchange announcement from Circio Holding ASA ("the Company") on April 8, 2026, where the Company announced the allocation of 23,148,148 new shares in the Company ("the Offer Shares") generating gross proceeds of approximately NOK 250 million ("Private Placement"), and a potential subsequent offering of up to 7,638,888 new shares generating gross proceeds of up to NOK 82.5 million at the same subscription price as in the private placement ("Subsequent Offering"). In the period since the announcement of the private placement, the Company's shares have traded below the subscription price, which is also the case at present. The trading volume on days when the shares have traded below the subscription price has been several times the full volume of the potential subsequent offering. Consequently, existing shareholders who did not participate in the private placement have had the opportunity to acquire shares in the Company at prices below the subscription price and reduce the dilutive effects of the private placement. Based on the above, the Company has decided to cancel the subsequent offering. This information is subject to disclosure requirements pursuant to section 5-12 of the Securities Trading Act. For further information, please contact: Erik Digman Wiklund, Chief Executive Officer Phone: +47 413 33 536 Email: erik.wiklund@circio.com Lubor Gaal, Chief Financial Officer Phone: +34 683 34 3811 Email: lubor.gaal@circio.com- ·33 min sittenIt is absolutely a positive signal when a company cancels a share issue because the market already prices the share lower – it can be interpreted as consideration for existing shareholders and a willingness to avoid unnecessary dilution. That being said, it's worth keeping a cool head and adding some nuance: * That the share issue was cancelled because the price is below NOK 10.80, also means that the market is currently not willing to price the company higher. It's not just “shareholder-friendliness”, but also a reality check. * “250 million in cash” and runway until 2030 sounds reassuring, but in biotech (which Circio operates in) the cost structure can change quickly – especially if clinical studies are expanded, delays occur, or new opportunities arise. * That they don't need money now, doesn't mean they will never raise more capital. Many such companies go through several rounds before commercialization. The most constructive question going forward is therefore: What are the actual triggers going forward? Typically it will be about: * Clinical data / milestones * Partnerships or licensing agreements * Regulation and progress in the pipeline If these deliver, the share issue risk becomes less problematic. If not, the capital requirement can return regardless of how much is in cash today. So yes – short-term this is a clear “plus” for shareholders. But the case still stands or falls on progress and results, not just capital structure.
- ·44 min sittenCIRCIO CANCELLED THE ISSUE. THAT IS GOOD NEWS. 🧬✅ Today Circio cancelled the planned issue of NOK 82.5 million. Why? Because the share has traded below the issue price of NOK 10.80 since April 8. The company believes existing shareholders have already had the opportunity to buy cheaper in the market. It is a shareholder-friendly decision. And the most important thing: 250 million is already in the cash. Runway until 2030 is secured. No new shares. No new dilusion. They don't need more money right now. We know what we own. ♟️🧱🍷
·32 min sittenFantastic news, and a bullish signal I would claim! 🔥
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
9 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 min sittenYou might be right about that—such things often happen faster than people expect, especially if a buyer with strong incentives suddenly appears or if the market turns. At the same time, it's easy to overestimate the pace. Sales processes often take time due to due diligence, negotiations, and regulatory matters, even when interest is high. What makes you think it could happen sooner than anticipated? Are there concrete signals, or more of a gut feeling based on the company's development?
- ·23 min sitten250 MILLION SEEMS LIKE LITTLE. BUT CIRCIO DOESN'T NEED MORE. 🧬♟️ Lilly spent $9.4 billion on two deals. BMS spent $1.5 billion. AbbVie $2.1 billion. And Circio? 250 million kroner. Here's what no one is talking about: Circio is not a pharmaceutical company. They are a platform. That means Big Pharma pays for the research. Not Circio. The ongoing CNS study with one of the world's five largest pharmaceutical companies? Fully financed by them. Circio holds the key. Others foot the bill. 250 million is enough because they don't need to finance everything themselves. They license the technology, bring in non-dilutive capital from partners, and build parallel collaborations while others pay to test. It's not a weakness to be small. It's the business model. We know what we own. ♟️🧱🍷·2 min sittenYou might be right about that—such things often happen faster than people expect, especially if a buyer with strong incentives suddenly appears or if the market turns. At the same time, it's easy to overestimate the pace. Sales processes often take time due to due diligence, negotiations, and regulatory matters, even when interest is high. What makes you think it could happen sooner than anticipated? Are there concrete signals, or more of a gut feeling based on the company's development?
- ·31 min sittenCircio Holding ASA: Cancellation of subsequent offering Reference is made to the stock exchange announcement from Circio Holding ASA ("the Company") on April 8, 2026, where the Company announced the allocation of 23,148,148 new shares in the Company ("the Offer Shares") generating gross proceeds of approximately NOK 250 million ("Private Placement"), and a potential subsequent offering of up to 7,638,888 new shares generating gross proceeds of up to NOK 82.5 million at the same subscription price as in the private placement ("Subsequent Offering"). In the period since the announcement of the private placement, the Company's shares have traded below the subscription price, which is also the case at present. The trading volume on days when the shares have traded below the subscription price has been several times the full volume of the potential subsequent offering. Consequently, existing shareholders who did not participate in the private placement have had the opportunity to acquire shares in the Company at prices below the subscription price and reduce the dilutive effects of the private placement. Based on the above, the Company has decided to cancel the subsequent offering. This information is subject to disclosure requirements pursuant to section 5-12 of the Securities Trading Act. For further information, please contact: Erik Digman Wiklund, Chief Executive Officer Phone: +47 413 33 536 Email: erik.wiklund@circio.com Lubor Gaal, Chief Financial Officer Phone: +34 683 34 3811 Email: lubor.gaal@circio.com
- ·33 min sittenIt is absolutely a positive signal when a company cancels a share issue because the market already prices the share lower – it can be interpreted as consideration for existing shareholders and a willingness to avoid unnecessary dilution. That being said, it's worth keeping a cool head and adding some nuance: * That the share issue was cancelled because the price is below NOK 10.80, also means that the market is currently not willing to price the company higher. It's not just “shareholder-friendliness”, but also a reality check. * “250 million in cash” and runway until 2030 sounds reassuring, but in biotech (which Circio operates in) the cost structure can change quickly – especially if clinical studies are expanded, delays occur, or new opportunities arise. * That they don't need money now, doesn't mean they will never raise more capital. Many such companies go through several rounds before commercialization. The most constructive question going forward is therefore: What are the actual triggers going forward? Typically it will be about: * Clinical data / milestones * Partnerships or licensing agreements * Regulation and progress in the pipeline If these deliver, the share issue risk becomes less problematic. If not, the capital requirement can return regardless of how much is in cash today. So yes – short-term this is a clear “plus” for shareholders. But the case still stands or falls on progress and results, not just capital structure.
- ·44 min sittenCIRCIO CANCELLED THE ISSUE. THAT IS GOOD NEWS. 🧬✅ Today Circio cancelled the planned issue of NOK 82.5 million. Why? Because the share has traded below the issue price of NOK 10.80 since April 8. The company believes existing shareholders have already had the opportunity to buy cheaper in the market. It is a shareholder-friendly decision. And the most important thing: 250 million is already in the cash. Runway until 2030 is secured. No new shares. No new dilusion. They don't need more money right now. We know what we own. ♟️🧱🍷·32 min sittenFantastic news, and a bullish signal I would claim! 🔥
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 480 | - | - | ||
| 515 | - | - | ||
| 82 | - | - | ||
| 393 | - | - | ||
| 7 050 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
9 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 min sittenYou might be right about that—such things often happen faster than people expect, especially if a buyer with strong incentives suddenly appears or if the market turns. At the same time, it's easy to overestimate the pace. Sales processes often take time due to due diligence, negotiations, and regulatory matters, even when interest is high. What makes you think it could happen sooner than anticipated? Are there concrete signals, or more of a gut feeling based on the company's development?
- ·23 min sitten250 MILLION SEEMS LIKE LITTLE. BUT CIRCIO DOESN'T NEED MORE. 🧬♟️ Lilly spent $9.4 billion on two deals. BMS spent $1.5 billion. AbbVie $2.1 billion. And Circio? 250 million kroner. Here's what no one is talking about: Circio is not a pharmaceutical company. They are a platform. That means Big Pharma pays for the research. Not Circio. The ongoing CNS study with one of the world's five largest pharmaceutical companies? Fully financed by them. Circio holds the key. Others foot the bill. 250 million is enough because they don't need to finance everything themselves. They license the technology, bring in non-dilutive capital from partners, and build parallel collaborations while others pay to test. It's not a weakness to be small. It's the business model. We know what we own. ♟️🧱🍷·2 min sittenYou might be right about that—such things often happen faster than people expect, especially if a buyer with strong incentives suddenly appears or if the market turns. At the same time, it's easy to overestimate the pace. Sales processes often take time due to due diligence, negotiations, and regulatory matters, even when interest is high. What makes you think it could happen sooner than anticipated? Are there concrete signals, or more of a gut feeling based on the company's development?
- ·31 min sittenCircio Holding ASA: Cancellation of subsequent offering Reference is made to the stock exchange announcement from Circio Holding ASA ("the Company") on April 8, 2026, where the Company announced the allocation of 23,148,148 new shares in the Company ("the Offer Shares") generating gross proceeds of approximately NOK 250 million ("Private Placement"), and a potential subsequent offering of up to 7,638,888 new shares generating gross proceeds of up to NOK 82.5 million at the same subscription price as in the private placement ("Subsequent Offering"). In the period since the announcement of the private placement, the Company's shares have traded below the subscription price, which is also the case at present. The trading volume on days when the shares have traded below the subscription price has been several times the full volume of the potential subsequent offering. Consequently, existing shareholders who did not participate in the private placement have had the opportunity to acquire shares in the Company at prices below the subscription price and reduce the dilutive effects of the private placement. Based on the above, the Company has decided to cancel the subsequent offering. This information is subject to disclosure requirements pursuant to section 5-12 of the Securities Trading Act. For further information, please contact: Erik Digman Wiklund, Chief Executive Officer Phone: +47 413 33 536 Email: erik.wiklund@circio.com Lubor Gaal, Chief Financial Officer Phone: +34 683 34 3811 Email: lubor.gaal@circio.com
- ·33 min sittenIt is absolutely a positive signal when a company cancels a share issue because the market already prices the share lower – it can be interpreted as consideration for existing shareholders and a willingness to avoid unnecessary dilution. That being said, it's worth keeping a cool head and adding some nuance: * That the share issue was cancelled because the price is below NOK 10.80, also means that the market is currently not willing to price the company higher. It's not just “shareholder-friendliness”, but also a reality check. * “250 million in cash” and runway until 2030 sounds reassuring, but in biotech (which Circio operates in) the cost structure can change quickly – especially if clinical studies are expanded, delays occur, or new opportunities arise. * That they don't need money now, doesn't mean they will never raise more capital. Many such companies go through several rounds before commercialization. The most constructive question going forward is therefore: What are the actual triggers going forward? Typically it will be about: * Clinical data / milestones * Partnerships or licensing agreements * Regulation and progress in the pipeline If these deliver, the share issue risk becomes less problematic. If not, the capital requirement can return regardless of how much is in cash today. So yes – short-term this is a clear “plus” for shareholders. But the case still stands or falls on progress and results, not just capital structure.
- ·44 min sittenCIRCIO CANCELLED THE ISSUE. THAT IS GOOD NEWS. 🧬✅ Today Circio cancelled the planned issue of NOK 82.5 million. Why? Because the share has traded below the issue price of NOK 10.80 since April 8. The company believes existing shareholders have already had the opportunity to buy cheaper in the market. It is a shareholder-friendly decision. And the most important thing: 250 million is already in the cash. Runway until 2030 is secured. No new shares. No new dilusion. They don't need more money right now. We know what we own. ♟️🧱🍷·32 min sittenFantastic news, and a bullish signal I would claim! 🔥
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 480 | - | - | ||
| 515 | - | - | ||
| 82 | - | - | ||
| 393 | - | - | ||
| 7 050 | - | - |
Välittäjätilasto
Dataa ei löytynyt